ArticleCancer management and research2025
Clinicopathological Features and Prognostic Factors of Renal Cell Carcinoma in Young Patients Under 45 Years: A Single-Center Retrospective Study.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the clinicopathological characteristics, diagnostic approaches, and therapeutic strategies for renal cell carcinoma (RCC) in young patients under 45 years of age, aiming to provide insights for early detection and improved prognosis. Methods: We retrospectively analyzed the clinical data of 150 RCC patients aged 18 to 45 years treated at the General Hospital of Ningxia Medical University from 2011 to 2023. Clinicopathological features, surgical outcomes, and long-term follow-up data were evaluated. Results: The study included 82 males and 68 females, with a mean age of 38.89 ± 5.56 years. Clear cell RCC was the most common subtype (72.6%), followed by chromophobe RCC (12%) and papillary RCC (4%). Other rare subtypes included XP11.2 translocation/TFE3 gene fusion - associated RCC (2.7%) and collecting duct RCC (0.7%). In terms of clinical staging, 89% of patients were classified as T1 stage. Follow - up data, ranging from 12 to 153 months, showed that 11 patients died of the disease and 14 exhibited metastasis. Postoperative glomerular filtration rate (GFR) and serum creatinine (CREA)) levels were lower than preoperative levels, and patients who underwent radical nephrectomy (RN) had worse renal function than those who underwent partial nephrectomy (PN). The 3 - year and 5 - year survival rates for the asymptomatic group were 100% and 97%, respectively, while for the symptomatic group, they were 94% and 83%, respectively. Single - factor Cox regression analysis revealed that symptoms, hypertension, clinical stage, pathological grade, and pathological type were independent risk factors for overall survival in young renal cancer patients. Conclusion: Young RCC patients present with unique clinicopathological characteristics and prognostic factors. Although the overall prognosis is relatively favorable, rare subtypes such as XP11.2 translocation/TFE3 gene fusion - associated RCC and collecting duct RCC are associated with worse outcomes. Early detection through regular physical examinations and prompt treatment are crucial for improving outcomes. PN should be prioritized when feasible, and effective management of comorbidities like hypertension is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.